Study Groups Paperdoll

Mucositis

Home > Study Groups > Mucositis

Leadership

Bossi 2022

Chair

Paolo Bossi, MD
Italy

Hannah Wardill

Vice-Chair

Hannah Wardill, PhD
Australia

How to Join

To join a study group, you must be a MASCC member.

  • Log in to your member account.
  • Click on Manage My Account/Profile.
  • Scroll down to your profile data and select “Edit”.
  • Then select the study group as one of your three study group selections. Click SAVE.

Have Questions?

Mission and Goals

The Mucositis Study Group’s major goal is to improve outcomes of patients experiencing oral and gastrointestinal mucositis associated with anticancer therapies. This study group works closely with the International Society of Oral Oncology (ISOO). Our objectives are to improve the design and conduct of clinical investigations, disseminate up-to-date educational information regarding mucositis, and serve as a resource for investigators in basic science, clinical, and health services research, as well as for industrial collaborators, clinicians, and patients.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla quam velit, vulputate eu pharetra nec, mattis ac neque. consectetur adipiscing elit. Nulla quam velit.
Joe Smith, XYZ Organization
Paolo Bossi, Brescia, Italy (2022)
“The Mucositis Study Group is a tremendous opportunity to get involved with the experts in this topic from all over the world.”
Sharon Elad, Rochester, NY, USA (2022)
“We, the Mucositis Study Group members, join forces to collaborate on research and to provide clinicians with better tools to assist their patients.”
Abhishek Kandwal, Dehradun, Uttarakhand, India (2022)
"Oral mucositis is a debilitating site effect of radiation therapy and chemotherapy. A standard protocol is very essential to provide relief in such patients”

Guidelines

Evidence-based clinical practice guidelines created by the Mucositis Study Group

Publications

Recent scientific publications from the Mucositis Study Group

Educational Recordings

Gastrointestinal Complications of Immunotherapy and Targeted Agents Prevention and Treatment Options

 

Oral Complications of Immunotherapies and TKIs: Similarities and Differences to Conventional Oral Mucositis